LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB:HEMA) today reported financial results for the six months ended June 30, 2015. For the period, revenue more than doubled to $4.29 million from $2.07 million, gross profit margin percentage improved to 43% from 21%, and loss from operations narrowed to $0.82 million from $2.61 million in the year-earlier period. Reflecting the recent sale of the Company’s Therapeutic Apheresis operations, Company total cash as of June 30 was $2.656 million, and there was no outstanding debt. Financial results for the year ended December 31, 2014 are available on the Company’s website.
Commenting on the results, HemaCare’s President and Chief Executive Officer, Pete van der Wal, stated, “2015 will be the first full year reflecting our sharpened focus on cell collection, processing and therapy, and we are pleased with our results for the first half of the year. Having completed the last of a series of divestitures of non-core businesses, we now have sufficient financial resources to build upon our early success in penetrating the emerging, rapid-growth cell therapy market.”
Help employers find you! Check out all the jobs and post your resume.
Commenting on the results, HemaCare’s President and Chief Executive Officer, Pete van der Wal, stated, “2015 will be the first full year reflecting our sharpened focus on cell collection, processing and therapy, and we are pleased with our results for the first half of the year. Having completed the last of a series of divestitures of non-core businesses, we now have sufficient financial resources to build upon our early success in penetrating the emerging, rapid-growth cell therapy market.”
Help employers find you! Check out all the jobs and post your resume.
